Evidence map›Paper›PMID 42768025›Full record

ArticleNature communications2026

Constitutive natural killer cell features associated with post-treatment control of SIV infection in the pVISCONTI study.

Anaïs Chapel, Luis Romero-Martín, Caroline Passaes, Valérie Monceaux, Stevenn Volant, Delphine Desjardins, Adeline Melard, Annie David, Nathalie Dereuddre-Bosquet, Christine Rouzioux and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anaïs Chapel *Institut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.
Luis Romero-Martín *Institut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.ORCID http://orcid.org/0000-0003-1509-4882
Caroline PassaesInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.ORCID http://orcid.org/0000-0002-0813-2521
Valérie MonceauxInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France.ORCID http://orcid.org/0000-0002-8599-2146
Stevenn VolantInstitut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France.
Delphine DesjardinsUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral Auto-immune, Hematological and Bacterial diseases (IMVA-HB/ IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-5820-3914
Adeline MelardUniversité Paris Cité, INSERM, U1016; CNRS, UMR8104, Paris, France.ORCID http://orcid.org/0000-0003-1207-0201
Annie DavidInstitut Pasteur, Université Paris Cité, HIV, Inflammation and Persistence Unit, Paris, France.
Nathalie Dereuddre-BosquetUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral Auto-immune, Hematological and Bacterial diseases (IMVA-HB/ IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0001-6682-6313
Christine RouziouxUniversité Paris Cité, Paris, France.
Véronique Avettand-FenoelUniversité Paris Cité, INSERM, U1016; CNRS, UMR8104, Paris, France.ORCID http://orcid.org/0000-0002-7022-2990
Michaela Müller-TrutwinInstitut Pasteur, Université Paris Cité, HIV, Inflammation and Persistence Unit, Paris, France.ORCID http://orcid.org/0000-0002-3854-2396
Roger Le GrandUniversité Paris-Saclay, CEA, INSERM, UMR1184, Immunology of Viral Auto-immune, Hematological and Bacterial diseases (IMVA-HB/ IDMIT Department), Fontenay-aux-Roses/Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-4928-4484
Asier Sáez-CiriónInstitut Pasteur, Université Paris Cité, Viral Reservoirs and Immune Control Unit, Paris, France. asier.saez-cirion@pasteur.fr.ORCID http://orcid.org/0000-0003-2406-7536

Funding

U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) UM1AI16456
6 · The paper itself

Abstract

Post-treatment HIV controllers (PTC) offer a unique opportunity to uncover the determinants of durable remission after antiretroviral therapy (ART) interruption. Here, using six PTC and six post-treatment non-controllers from the pVISCONTI study in cynomolgus macaques, we identify associations between Natural Killer (NK) cell subsets and outcomes following ART interruption. NKG2Ahigh NK cells lacking NKp30/NKp46 (NKG2AhighNKp30-NKp46-), shaped by the MHC backgrounds of the animals, were linked to improved post-treatment control; this NK subset displayed tissue-homing potential and preserved functionality despite infection, characterized by cytokine production and degranulation. Conversely, NKG2AlowNKp30 + NKp46+ NK cells exhibited reduced cytotoxic potential and elevated IL-10/IL-17A production, and their pre-infection levels were associated with higher viremia and larger viral reservoirs after ART interruption. Our study suggests that constitutive NK cell features, preserved by early ART initiation, may provide a favorable immune environment for post-treatment control. Our findings identify the NKG2A axis as a potential target to improve outcomes after ART interruption.

Indexed as

Killer Cells, NaturalSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAnti-Retroviral AgentsMacaca fascicularisMaleNatural Cytotoxicity Triggering Receptor 1Natural Cytotoxicity Triggering Receptor 3NK Cell Lectin-Like Receptor Subfamily CViral LoadViremiaAnti-Retroviral AgentsNatural Cytotoxicity Triggering Receptor 1Natural Cytotoxicity Triggering Receptor 3NK Cell Lectin-Like Receptor Subfamily C

Identifiers

PMID42768025
PMCPMC13594178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.